skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 26  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 next page
Refined by: Database: HighWire Press (Free Journals) remove subject: Studies remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies
OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies
Material Type:
Article 		Add to My Research

OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.66 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.3110

Full text available

Citations Cited by
2
AB0614 The lupus studies: the european and spanish point of view
AB0614 The lupus studies: the european and spanish point of view
Material Type:
Article 		Add to My Research

AB0614 The lupus studies: the european and spanish point of view

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1456 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.2893

Full text available

Citations Cited by
3
OP0036 A phase 3 randomised, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective jak-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic dmards
OP0036 A phase 3 randomised, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective jak-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic dmards
Material Type:
Article 		Add to My Research

OP0036 A phase 3 randomised, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective jak-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic dmards

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.68 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.3131

Full text available

Citations Cited by
4
THU0306 Clinical specialty setting as a determinant for disease management in patients with psoriatic arthritis: results from loop, a cross-sectional, multi-country, observational study
THU0306 Clinical specialty setting as a determinant for disease management in patients with psoriatic arthritis: results from loop, a cross-sectional, multi-country, observational study
Material Type:
Article 		Add to My Research

THU0306 Clinical specialty setting as a determinant for disease management in patients with psoriatic arthritis: results from loop, a cross-sectional, multi-country, observational study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.371 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.2004

Full text available

Citations Cited by
5
SAT0200 Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study
SAT0200 Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study
Material Type:
Article 		Add to My Research

SAT0200 Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.960 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.1947

Full text available

Citations Cited by
6
OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate
OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate
Material Type:
Article 		Add to My Research

OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.67 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.4237

Full text available

Citations Cited by
7
FRI0530 Total joint replacement (TJR) as clinical endpoint in oa; prevalence and incidence rates of tjrs from the prospective epidemiologic risk factor (PERF I) study
FRI0530 Total joint replacement (TJR) as clinical endpoint in oa; prevalence and incidence rates of tjrs from the prospective epidemiologic risk factor (PERF I) study
Material Type:
Article 		Add to My Research

FRI0530 Total joint replacement (TJR) as clinical endpoint in oa; prevalence and incidence rates of tjrs from the prospective epidemiologic risk factor (PERF I) study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.791 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.7003

Full text available

Citations Cited by
8
AB1276 Economic impact of non-medical switching from originator biologics to biosimilars – a systematic literature review
AB1276 Economic impact of non-medical switching from originator biologics to biosimilars – a systematic literature review
Material Type:
Article 		Add to My Research

AB1276 Economic impact of non-medical switching from originator biologics to biosimilars – a systematic literature review

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1731 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.4975

Full text available

Citations Cited by
9
Influence of Natural American Spirit advertising on current and former smokers’ perceptions and intentions
Influence of Natural American Spirit advertising on current and former smokers’ perceptions and intentions
Material Type:
Article 		Add to My Research

Influence of Natural American Spirit advertising on current and former smokers’ perceptions and intentions

Tobacco control, 2018-09, Vol.27 (5), p.498-504 [Peer Reviewed Journal]

Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;ISSN: 0964-4563 ;EISSN: 1468-3318 ;DOI: 10.1136/tobaccocontrol-2017-053881 ;PMID: 29055882

Full text available

Citations Cited by
10
OP0050 The treatment gap after fracture in osteoporosis patients in sweden
OP0050 The treatment gap after fracture in osteoporosis patients in sweden
Material Type:
Article 		Add to My Research

OP0050 The treatment gap after fracture in osteoporosis patients in sweden

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.72 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-eular.3397

Full text available

Citations Cited by
11
THU0191 Effects of tofacitinib, an oral janus kinase inhibitor, on patient-reported outcomes in japanese patients with rheumatoid arthritis
THU0191 Effects of tofacitinib, an oral janus kinase inhibitor, on patient-reported outcomes in japanese patients with rheumatoid arthritis
Material Type:
Article 		Add to My Research

THU0191 Effects of tofacitinib, an oral janus kinase inhibitor, on patient-reported outcomes in japanese patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.274 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-eular.1402

Full text available

Citations Cited by
12
AB0947 Impact of clinical specialty setting on disease management in patients with psoriatic arthritis: results from a cross-sectional observational study in the united states
AB0947 Impact of clinical specialty setting on disease management in patients with psoriatic arthritis: results from a cross-sectional observational study in the united states
Material Type:
Article 		Add to My Research

AB0947 Impact of clinical specialty setting on disease management in patients with psoriatic arthritis: results from a cross-sectional observational study in the united states

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1598 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.1986

Full text available

Citations Cited by
13
OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial
OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial
Material Type:
Article 		Add to My Research

OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.200 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.2140

Full text available

Citations Cited by
14
SAT0240 Vagus nerve stimulation in patients with rheumatoid arthritis: two-year safety and efficacy
SAT0240 Vagus nerve stimulation in patients with rheumatoid arthritis: two-year safety and efficacy
Material Type:
Article 		Add to My Research

SAT0240 Vagus nerve stimulation in patients with rheumatoid arthritis: two-year safety and efficacy

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.981 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.1802

Full text available

Citations Cited by
15
OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab
OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab
Material Type:
Article 		Add to My Research

OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.217 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.2891

Full text available

Citations Cited by
16
FRI0588 Interim results of a phase 2 study of XMAB®5871, a reversible B cell inhibitor, in IGG4-related disease
FRI0588 Interim results of a phase 2 study of XMAB®5871, a reversible B cell inhibitor, in IGG4-related disease
Material Type:
Article 		Add to My Research

FRI0588 Interim results of a phase 2 study of XMAB®5871, a reversible B cell inhibitor, in IGG4-related disease

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.711 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-eular.3301

Full text available

Citations Cited by
17
THU0124 Low inflammation on magnetic resonance imaging in patients with rheumatoid arthritis that achieved sustained clinical remission on adalimumab: data from the predictra study
THU0124 Low inflammation on magnetic resonance imaging in patients with rheumatoid arthritis that achieved sustained clinical remission on adalimumab: data from the predictra study
Material Type:
Article 		Add to My Research

THU0124 Low inflammation on magnetic resonance imaging in patients with rheumatoid arthritis that achieved sustained clinical remission on adalimumab: data from the predictra study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.283 [Peer Reviewed Journal]

2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.4804

Full text available

Citations Cited by
18
SAT0187 Safety, pharmacokinetics and efficacy of e6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study in rheumatoid arthritis; addtional data of 400 mg cohort
SAT0187 Safety, pharmacokinetics and efficacy of e6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study in rheumatoid arthritis; addtional data of 400 mg cohort
Material Type:
Article 		Add to My Research

SAT0187 Safety, pharmacokinetics and efficacy of e6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study in rheumatoid arthritis; addtional data of 400 mg cohort

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.842 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-eular.1401

Full text available

Citations Cited by
19
FRI0496 Comparing tofacitinib safety profile in patients with psoriatic arthritis in clinical studies with real-world data
FRI0496 Comparing tofacitinib safety profile in patients with psoriatic arthritis in clinical studies with real-world data
Material Type:
Article 		Add to My Research

FRI0496 Comparing tofacitinib safety profile in patients with psoriatic arthritis in clinical studies with real-world data

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.676 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-eular.2448

Full text available

Citations Cited by
20
SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
Material Type:
Article 		Add to My Research

SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1010 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.3115

Full text available

Citations Cited by

Results 1 - 20 of 26  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait